Finley; Don Richard

Patent Applications and Registrations

Patent applications and USPTO patent grants for Finley; Don Richard.The latest application filed is for "histamine h3 receptor agents, preparation and therapeutic uses".

Company Profile

0.10.12

Finley; Don Richard - Greenwood IN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Histamine H3 receptor agents, preparation and therapeutic uses Grant 8,008,301 - Beavers , et al. August 30, 2	2011-08-30
Histamine H3 receptor agents, preparation and therapeutic uses Grant 8,008,296 - Beavers , et al. August 30, 2	2011-08-30
Pyrrolidine derivatives as histamine H3 receptor antagonists Grant 7,951,826 - Beavers , et al. May 31, 2	2011-05-31
Histamine H3 Receptor Agents, Preparation And Therapeutic Uses App 20100160319 - Beavers; Lisa Selsam ; et al.	2010-06-24
Histamine H3 receptor agents, preparation and therapeutic uses Grant 7,705,025 - Finley , et al. April 27, 2	2010-04-27
Histamine H3 Receptor Agents, Preparation And Therapeutic Uses App 20100048580 - Beavers; Lisa Selsam ; et al.	2010-02-25
Histamine H3 Receptor Agents, Preparation and Therapeutic Uses App 20100029608 - FINLEY; Don Richard ; et al.	2010-02-04
Histamine H3 Receptor Agents, Preparation And Therapeutic Uses App 20090048225 - Finley; Don Richard ; et al.	2009-02-19
Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists App 20080207732 - Beavers; Lisa Selsam ; et al.	2008-08-28
Histamine H3 Receptor Agents, Preparation And Therapeutic Uses App 20070208024 - Beavers; Lisa Selsam ; et al.	2007-09-06
2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as .beta..sub.3 agonists Grant 7,214,697 - Jesudason , et al. May 8, 2	2007-05-08
.beta.3 adrenergic agonists Grant 7,208,505 - Sall , et al. April 24, 2	2007-04-24
3-substituted oxindole .beta.3 agonists Grant 7,087,635 - Sall , et al. August 8, 2	2006-08-08
Histamine h3 receptor antagonists, preparation and therapeutic uses App 20060167046 - Beavers; Lisa Selsam ; et al.	2006-07-27
2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as .beta..sub.3 agonists Grant 7,009,060 - Jesudason , et al. March 7, 2	2006-03-07
2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists App 20060014963 - Jesudason; Cynthia Darshini ; et al.	2006-01-19
3-Substituted oxindole beta3 agonists App 20050159473 - Sall, Daniel Jon ; et al.	2005-07-21
3-substituted oxindole .beta.-3 agonists Grant 6,911,463 - Sall , et al. June 28, 2	2005-06-28
Beta 3 adrenergic agonists App 20050080110 - Sall, Daniel Jon ; et al.	2005-04-14
2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists App 20050014741 - Darshini, Cynthia Richard ; et al.	2005-01-20
3-substituted oxindole beta-3 agonists App 20040242668 - Sall, Daniel Jon ; et al.	2004-12-02
Pyridine compounds, intermediates compositions and methods of use Grant 5,672,609 - Bryant , et al. September 30, 1	1997-09-30

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.